IDEXX Laboratories, Inc. earnings overview

IDXX FY2026 Q1 · Calendar Q2 2026

IDEXX Laboratories, Inc.

IDEXX Laboratories opened fiscal 2026 with a beat-and-raise quarter, exceeding consensus on both revenue and EPS and upgrading full-year guidance from maintained to raised. The results were anchored by CAG Diagnostics recurring revenue, which ran 1,100 basis points ahead of declining U.S. clinical visits, demonstrating that diagnostic intensity per visit continues to expand even as wellness-visit traffic softens. Premium instrument momentum persisted with 1,100 inVue Dx placements in the quarter toward a 5,500-unit annual target, and international markets delivered double-digit growth highlighted by Cancer DX launches in Europe and Australia. The quarter also brought a CEO transition announcement, with Mike Erickson succeeding Jay Mazelsky. Headwinds included a $5 million equity-investment loss that weighed on Q1 earnings and supply-chain disruptions in the Middle East that pressured…